Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Male Sexual Response: Erection & Ejaculation

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Valosin-Containing Protein (VCP)/p97 Expression Correlation of Prognosis of Clear Cell Renal Cell Carcinomas.

Biomedicines·2026

Same author

Sexual dysfunctions in male patients with infertility: recommendations from the Fifth International Consultation for Sexual Medicine (ICSM 2024).

Sexual medicine reviews·2026

Same author

History of Peyronie's disease: from early descriptions to modern treatments.

Sexual medicine reviews·2025

Same author

Scoping review to assess the role of the immune system in the pathophysiology of vulvodynia and post-orgasmic illness syndrome.

Sexual medicine reviews·2025

Same author

Addressing unmet needs for patients with erectile dysfunction: a narrative review of topical therapies.

Sexual medicine·2025

Same author

[Multicentric Screening of Local Antibiotic Resistance in Uncomplicated Urinary System Infections: 1850 Patients from 37 Centers].

Mikrobiyoloji bulteni·2025

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

5-alpha reductase inhibitors and erectile dysfunction: the connection.

Fikret Erdemir¹, Andrew Harbin, Wayne J G Hellstrom

¹Tulane University-Department of Urology, New Orleans, LA, USA.

The Journal of Sexual Medicine

|December 19, 2008

Summary

5alpha-reductase inhibitors (5ARIs) are linked to sexual side effects like erectile dysfunction. While these effects are common, their exact causes remain unclear, necessitating further research into their mechanisms.

Related Experiment Videos

Last Updated: Jun 27, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Urology
Pharmacology
Men's Health

Background:

Benign prostatic hyperplasia (BPH) is prevalent in aging men.
Common treatments for BPH include alpha-blockers and 5alpha-reductase inhibitors (5ARIs).
5ARIs are associated with adverse sexual outcomes, including erectile dysfunction (ED), ejaculatory dysfunction (EjD), and decreased libido.

Purpose of the Study:

To review the literature on 5ARIs and their associated sexual adverse effects (AEs).
To explore proposed mechanisms underlying 5ARI-induced sexual dysfunction.

Main Methods:

A comprehensive literature review was performed.
Databases searched included MEDLINE and PubMed.
Studies focusing on 5ARIs and sexual AEs were analyzed.

Main Results:

Sexual AEs, including ED, EjD, and decreased libido, are reported in 2.1% to 38% of patients.
These effects typically manifest early in treatment and may diminish over time.
A potential mechanism involves reduced nitric oxide synthase activity secondary to decreased dihydrotestosterone levels.

Conclusions:

The association between 5ARIs and sexual dysfunction is evident in existing literature.
The precise pathophysiological mechanisms remain largely unknown.
Future research should focus on elucidating these mechanisms to guide prevention and treatment strategies.